Mass spectrometric approaches to assess the biodistribution and fate of cationic surfactants used as drug delivery nanoparticles

在制药行业，增长最快的领域是药物递送，目前占总价值的800多亿美元，包括基因递送。随着欧盟最近首次批准Glybera®基因疗法治疗遗传性血脂紊乱，后者获得了发展势头。事实上，有5000种遗传病是无法治愈的。因此，进行了2000多项临床试验(即人体试验)，评估各种基因治疗策略也就不足为奇了。

In the pharmaceutical industry, the fastest growing area is drug delivery, accounting currently for more than $80 billion of total value, including gene delivery. The latter has gained momentum with the recent first approval in the European Union of the gene therapy, Glybera® for the treatment of genetic lipid disorders. In fact, there are 5000 genetic diseases that do not have a cure. Therefore, it is not surprising that over 2000 clinical trials (i.e. human testing) have been conducted, evaluating various gene therapy strategies.